Multiple myeloma patients participating in the international MM-015 study will continue to receive Revlimid maintenance treatment, despite concern that there might be a link between such treatment and a higher risk of developing second cancers.  Celgene, the manufacturer of Revlimid, confirmed yesterday that no changes are currently planned for the trial protocol.

In a statement provided to The Myeloma Beacon, Dr. Antonio Palumbo, chief of the Myeloma Unit at the University of Torino in Italy and lead investigator of the MM-015 study, suggested that the benefits of Revlimid (lenalidomide) maintenance therapy …

After a week of discussions about the potential link between Revlimid maintenance therapy and second cancers, the members of the International Myeloma Working Group have decided that more information is needed before they can issue unified recommendations.

A number of myeloma specialists have voiced differing opinions on whether this potential link to second cancers should affect the use of Revlimid (lenalidomide) as a myeloma therapy (see related Beacon news).  The latest decision from the International Myeloma Working Group (IMWG) provides a clearer indication that there is a lack of consensus …

A split may be developing in the multiple myeloma research community regarding the treatment implications of a possible link between long-term Revlimid use and secondary cancers.

Many researchers are going on record saying the current controversy does not justify any change in the use of Revlimid (lenalidomide) as a myeloma therapy.  Other researchers, however, believe the controversy raises important questions that justify more cautious use of the drug.

Concerns about a potential Revlimid-secondary cancer link first emerged at the American Hematology Society annual meeting in December.  At the meeting, results were …

The Myeloma Beacon has learned that the Cancer and Leukemia Group B, the cooperative group running the CALGB / ECOG / BMT-CTN 100104 Revlimid maintenance trial, currently has no plans to halt Revlimid therapy in its trial.

The CALGB trial is one of three trials which released data last December that raised concerns about a potential link between long-term Revlimid (lenalidomide) use and second cases of cancer in multiple myeloma patients.

Among the 231 patients in the Revlimid maintenance arm of the CALGB trial, 15 second cancers have been reported.  Among …

Several investment bank reports published this week have heightened concern about a potential link between Revlimid and second cancers in multiple myeloma patients.  The reports have unnerved investors to such a degree that the stock of Celgene, Revlimid’s manufacturer, is down almost nine percent since the middle of last week.

Apprehension about Revlimid (lenalidomide) and secondary cancer first surfaced in December during the American Society of Hematology (ASH) annual meeting.  At the meeting, results were presented from three trials studying long-term Revlimid use.  All three trials showed more cases of …

New information was released last week regarding long-term treatment with Revlimid and a multiple myeloma patient’s risk of developing a second cancer.

The information is based on analyses prompted by results from three clinical trials presented at the American Society of Hematology meeting last month.  In each of the three trials, more multiple myeloma patients receiving Revlimid maintenance therapy reported developing a secondary cancer than patients who did not receive maintenance therapy.

Celgene, the manufacturer of Revlimid (lenalidomide), announced the results of the follow-up analyses during a quarterly earnings conference …